MDG1.DE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 17:36):

Stats
Dagens volum	44 837.00
Gjennomsnittsvolum	30 393.00
Markedsverdi	44.36M
EPS	€0 ( 2024-04-25 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-2.39
ATR14	€0.0330 (2.17%)

Volum Korrelasjon

Lang: -0.06 (neutral)

Kort: -0.25 (neutral)

Signal:(47.641) Neutral

Medigene AG Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Medigene AG Korrelasjon - Valuta/Råvare

0.61
( weak )

0.52
( weak )

0.00
( neutral )

0.59
( weak )

-0.39
( neutral )

0.31
( neutral )

Medigene AG Økonomi

Annual	2023
Omsetning:	€6.03M
Bruttogevinst:	€2.98M (49.40 %)
EPS:	€-0.660

FY	2023
Omsetning:	€6.03M
Bruttogevinst:	€2.98M (49.40 %)
EPS:	€-0.660

FY	2023
Omsetning:	€0
Bruttogevinst:	€0 (0.00 %)
EPS:	€0

FY	2022
Omsetning:	€31.25M
Bruttogevinst:	€29.26M (93.65 %)
EPS:	€-0.340

Financial Reports:

No articles found.

Medigene AG

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.